- Home
- JBGS vs BBNX Comparison
JBGS vs BBNX Comparison
Compare JBGS & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JBGS | BBNX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2025 |
Fundamental Metrics
Financial Performance| Metric | JBGS | BBNX |
|---|---|---|
| Price | $18.04 | $29.41 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $16.50 | ★ $28.09 |
| AVG Volume (30 Days) | ★ 722.3K | 497.1K |
| Earning Date | 10-28-2025 | 10-28-2025 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $501,226,000.00 | $88,570,000.00 |
| Revenue This Year | N/A | $52.13 |
| Revenue Next Year | $1.79 | $36.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.01 |
| 52 Week Low | $13.28 | $8.89 |
| 52 Week High | $24.30 | $32.71 |
Technical Indicators
Market Signals| Indicator | JBGS | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 58.38 |
| Support Level | $17.36 | $26.13 |
| Resistance Level | $18.69 | $32.71 |
| Average True Range (ATR) | 0.58 | 2.05 |
| MACD | 0.14 | 0.06 |
| Stochastic Oscillator | 60.69 | 49.70 |
Price Performance
Historical ComparisonAbout JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.